SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-140533
Filing Date
2021-04-29
Accepted
2021-04-29 16:25:07
Documents
18
Period of Report
2021-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d163605d8k.htm   iXBRL 8-K 33392
2 EX-1.1 d163605dex11.htm EX-1.1 232747
3 EX-5.1 d163605dex51.htm EX-5.1 6965
4 EX-99.1 d163605dex991.htm EX-99.1 8395
5 EX-99.2 d163605dex992.htm EX-99.2 9222
9 GRAPHIC g163605dsp56.jpg GRAPHIC 11955
10 GRAPHIC g163605g0429074339239.jpg GRAPHIC 6757
  Complete submission text file 0001193125-21-140533.txt   519402

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA aldx-20210427.xsd EX-101.SCH 3094
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20210427_lab.xml EX-101.LAB 18139
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20210427_pre.xml EX-101.PRE 11424
11 EXTRACTED XBRL INSTANCE DOCUMENT d163605d8k_htm.xml XML 3362
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 21871057
SIC: 2834 Pharmaceutical Preparations